Merck, Eisai Get FDA OK of Welireg/Lenvima Combo in Kidney Cancer

By Colin KellaherMerck and Eisai have won U.S. Food and Drug Administration approval of the dual oral regimen of Merck's Welireg plus both companies' Lenvima in certain patients with the most common type of kidney cancer.The companies on Friday said the green light covers the combination in adults…